MedElevator
Войти в исследования Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zaurito Paolo, Scilipoti Pietro, Longoni Mattia, de Angelis Mario, Ślusarczyk Aleksander, Viti Alessandro, Santangelo Alfonso, Tremolada Giovanni, Soria Francesco, Pradere Benjamin, Krajewski Wojciech, D'Andrea David, Mari Andrea, Giudice Francesco Del, Pichler Renate, Subiela José Daniel, Marcq Gautier, Gallioli Andrea, Afferi Luca, Mastroianni Riccardo, Simone Giuseppe, Albisinni Simone, Mertens Laura S, Laukhtina Ekaterina, Oberneder Katharina, Elena José Luis Rodríguez, Aranda Javier, Puentedura Alfonso Lafuente, Velasco Jorge Caño, Contieri Roberto, Hurle Rodolfo, Mori Keiichiro, Radziszewski Piotr, Shariat Shahrokh F, Gontero Paolo, Rouprêt Morgan, Montorsi Francesco, Salonia Andrea, Briganti Alberto, Moschini Marco, European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group
Аннотация
METHODS: We identified 529 TaHG patients without carcinoma in situ (CIS) treated with BCG from 16 tertiary centers between 2003 and 2024. BCG failure was defined as the development of BCG-unresponsive status, BCG relapsing status or identification of muscle invasive bladder cancer during follow-up. TaHG patients were stratified according to the number of EAU and AUA risk factors in three groups (0, 1, 2-3 risk factors), and in intermediate risk (IR-TaHG) and high-risk (HR-TaHG) according to both EAU and AUA risk stratifications. Cumulative incidence analyses and Cox regression models analyzed the 5-yr risk of HG-recurrence, progression and BCG failure among TaHG patients stratified according to the number of EAU and AUA risk factors.
KEY FINDINGS: At a median follow-up of 40 months (IQR: 37-42), 114 (22%) TaHG patients experienced a HG-recurrence, 49 (9%) patients had progression and 107 (20%) had BCG failure. No differences in the risk of HG-recurrence, progression and rates of BCG failure were detected in TaHG patients stratified according to the number of EAU or AUA risk factors (all P < 0.05). No differences in the risk of 5-year HG-recurrence were observed between IR-TaHG and HR-TaHG patients according to both EAU (26% vs. 31%, P = 0.10) and AUA risk stratifications (24% vs. 29%, P = 0.07). Similarly, no differences in the 5-yr risk of progression were detected among IR-TaHG and HR-TaHG according to EAU (13% vs. 15%, P = 0.3) and AUA risk stratifications (12% vs. 15%, P = 0.2). No differences in the risk of BCG failure were observed between IR-TaHG and HR-TaHG according to both EAU and AUA risk stratifications (all P > 0.05).
CONCLUSION AND CLINICAL IMPLICATIONS: We observed no differences in HG-recurrence, progression, or BCG failure rates among patients with TaHG NMIBC, regardless of the number of EAU or AUA risk factors harbored. These findings may speculatively support the increasing need for BCG-adapted risk stratification and the consideration of all TaHG tumors without CIS as a homogenous population with a similar oncological risk, regardless of individual risk factors.